Beukes hip dysplasia is an autosomal dominant disease which has to date been described only in a large South African family of Dutch origin. The patients presented with progressive epiphyseal dysplasia limited to femoral capital epiphysis and their height was not significantly reduced.
A unique variant of the ubiquitin-fold modifier 1 (Ufm1)-specific peptidase 2 (UFSP2) gene (c.868T>C) has been reported in all individuals from Beukes family with clinical and radiological diagnosis of Beukes hip dysplasia. Three individuals, propositus, mother, and grandmother, presented with short stature, joint pain, genu vara and a novel spondyloepimetaphyseal dysplasia involving epiphyses predominantly at hips, but also at knees, ankles, wrists and hands, associated with variable degrees of metaphysis and spine involvement. Exome sequencing allowed us to identify the heterozygous variant c.1277A>C of the UFSP2 gene, leading to the missense change p.D426A, in all 3 patients. This mutation is predicted as damaging and, similarly to the mutation originally described in the Beukes family (p. Y290H), directly affects one of the cata- The affected family members presented with hip pain in early childhood and progressive hip dysplasia, which needed early hip replacement. No other skeletal abnormalities were identified and affected persons were not significantly smaller than their unaffected relatives of the same age and sex. 1 Further investigations of this family made use of a genome-wide screen with a panel of 290 markers, with an average spacing of 11 cm, that mapped the Beukes hip dysplasia locus to chromosome 4q35. 2 Watson refined the disease-linked region and screened genes for potentially causative mutations, finding a novel heterozygous variant, c.868T>C (leading to p.Y290H), of the ubiquitin-fold modifier 1 (Ufm1)-specific peptidase 2 (UFSP2) gene. To check that no additional candidate disease-causing variant was present within the candidate interval, 3 distantly related affected family members were subjected to whole-exome sequencing (WES) which confirmed the UFSP2 c.868T>C variant as the only shared genetic change. 3 We have studied an Italian family with 3 affected subjects showing short stature and a distinct skeletal dysplasia which was not limited to hip. Because of the impossibility to recognize a known skeletal dysplasia, WES was performed, showing a new mutation of the UFSP2 gene shared by the 3 patients.
| METHODS
Biological samples were collected from the family after informed consent for genetic study, according to institutional Helsinki committee.
The family consented publication for clinical and genetic data.
| Subjects
The propositus was born at thirty-third week of pregnancy with form of skeletal dysplasia, the Beukes hip dysplasia. This mutation was not only predicted to be pathogenic but also never reported before, having been found absent from all the DNA sequence variant databases inquired, as well as from genetic data of >60 unrelated individuals subjected to WES in our lab. In addition, the above mentioned UFSP2 p.D426A variant could also be localized to the active that these patients present an unique disease entity.
WES allowed us to identify the heterozygous variant c.1277A>C
(p.D426A) of the UFSP2 gene in all the affected members of the family under study. This mutation is predicted as damaging by numerous softwares (Polyphen-2, SIFT, Mutation Taster2, etc.), with a CADD score >20. In addition, we found that it directly affects one of the catalytic residues participating in the active site of the protein.
Indeed, a thorough investigation has already shown that residue authors named Cys294, Asp418, and His420 (corresponding to NM_018359 residues Cys302, Asp426, and His428) are the bona fide catalytic residues for UFSP2. 6 in vitro mutagenesis studies, carried out by the same authors to understand the loss of catalytic activity observed in different UFSP2 mutants, allowed to show the persistence of only a residual activity for the D418A mutant, corresponding to the same mutation found in our family, D426A. Ha et al. 6 further showed that residues Cys294 (NM_018359 Cys302) and His420 (NM_018359 His428) are directly involved in the catalytic reaction, whereas Asp418 (NM_018359 Asp426) is "essential in stabilizing the transition state through electrostatic interactions." Therefore, the residual activity they saw for the D418A mutant may be due to the aid of the His398 (NM_018359 His406) residue 6 .
Surprisingly, in comparison with skeletal dysplasia recurring in the Italian family reported here, the clinical phenotype in the affected South-African family was limited to hip dysplasia which needed early hip replacement. 1 .
UFSP2 encodes a highly conserved cysteine protease, which cleaves 2 C-terminal residues from ubiquitin-fold modifier 1(Ufm1), a ubiquitin-like post-translational modifier protein. Activation of ubiquitin-fold modifier 1 by the encoded protein exposes a C-terminal glycine residue that allows interaction with other proteins and its transfer to target proteins.
Ufm1 cascade has been implicated in endoplasmic reticulum functions and cell cycle control, but its biological role still remains poorly understood. 8 However, the Ufm1 system seems to have a role during osteogenesis; indeed, by radioactive mRNA in situ hybridization no UFSP2 expression was detected in embryonic and newborn mouse, but distinctive patterns of expression were observed in a 10-day old mouse. In particular, the UFSP2 expression was localized to the bone, ligaments and muscle in hip and knee, and also detected in the spine . 9 These observations could explain a wide skeletal dysplasia, not limited to hip, thus accounting for the more complex skeletal phenotype reported in our family.
